These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37364158)

  • 1. Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta-analysis.
    Martins-de-Barros AV; Silva CCG; Gonçalves KKN; de Albuquerque Cavalcanti Almeida R; de Oliveira E Silva ED; da Costa Araújo FA; Robinson L; van Heerden WFP; de Vasconcelos Carvalho M
    J Oral Pathol Med; 2023 Sep; 52(8):701-709. PubMed ID: 37364158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: Systematic review and meta-analysis.
    Martins-de-Barros AV; Anjos RSD; Silva CCG; Silva EDOE; Araújo FADC; Carvalho MV
    J Oral Pathol Med; 2022 Mar; 51(3):223-230. PubMed ID: 35090195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
    González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R
    World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
    Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
    Pei J; Zhang L; Jia YX; Chen WH
    Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
    Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
    Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of MDM2 Overexpression in Ameloblastomas with
    Tosios KI; Kalogirou EM; Koutlas IG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
    Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
    Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Mamat Yusof MN; Ch'ng ES; Radhiah Abdul Rahman N
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
    Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
    Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
    do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
    Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.
    Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM
    Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
    Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
    Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
    Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of BRAF p.V600E and Detection Methods in Benign Mixed and Malignant Odontogenic Tumors: A Systematic Review.
    Severino-Lazo RJG; de Vasconcelos Carvalho M; Campello CP; Moraes SLD; do Egito Vasconcelos BC; Pellizzer EP
    Head Neck Pathol; 2023 Dec; 17(4):1000-1010. PubMed ID: 38057461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
    Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
    J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
    Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF p.V600E Mutational Status Does Not Correlate with Biological Behavior in Conventional Ameloblastomas: A Disease-Free Survival Analysis.
    Martins-de-Barros AV; da Costa Araújo FA; Faro TF; de Aquino AAT; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; de Oliveira E Silva ED; de Vasconcelos Carvalho M
    Head Neck Pathol; 2024 Mar; 18(1):23. PubMed ID: 38504068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
    Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
    Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
    Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
    J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.